Shares of medical-device maker Cyberonics Inc. tumbled in Thursday morning trading after an analyst said past stock options granted to executives showed "unusual activity." SunTrust Robinson Humphrey analyst Amit Hazan said in a note he analyzed all the companies he covers and found that Cyberonics granted options to three executives, including Chief Executive Skip Cummins, on June 15, 2004, while the stock was halted just after a Food and Drug Administration panel recommended approval of the company's pacemaker-like medical device, VNS Therapy, to treat major depression.
The Houston Chronicle
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Theradiag Snags CE Mark for Biotherapy Monitoring Analyzer
The i-Track10 can be integrated into laboratory automation systems and features random access analysis and continuous loading capabilities.
Petition Urges FDA, DEA to Classify Tramadol as a Schedule II Controlled Substance
The DEA classified tramadol as a Schedule IV controlled substance in 2014.
FDAnews Device Daily Bulletin
CYBERONICS DOWNGRADED ON STOCK OPTIONS
June 9, 2006
